KNSA
Kiniksa Pharmaceuticals International, plc
Key Financials
Net Income
$59.0M
↑ 236.6%
Operating Income
$77.2M
↑ 269.3%
Revenue
$677.6M
↑ 60.1%
EPS (Diluted)
$0.75
↑ 225.0%
Total Assets
$763.6M
↑ 31.5%
Shareholders' Equity
$567.6M
↑ 29.5%
Total Liabilities
$196.0M
↑ 37.9%
Cash & Equivalents
$165.6M
↓ 9.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 6/2/2026 | View on SEC |
| 4 | 6/2/2026 | View on SEC |
| 4 | 6/2/2026 | View on SEC |
| 4 | 6/2/2026 | View on SEC |
| 4 | 6/2/2026 | View on SEC |
| 4 | 6/2/2026 | View on SEC |
| 4 | 6/2/2026 | View on SEC |
| 4 | 6/2/2026 | View on SEC |
| 8-K | 5/29/2026 | View on SEC |
| SCHEDULE 13D/A | 5/26/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | KNSA |
| Company Name | Kiniksa Pharmaceuticals International, plc |
| CIK | 1730430 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | 7814319100 |